
Subject	Evaluation Advisory Committee Chair Report
---------	--

Category	For Information
----------	-----------------

Section A: Introduction

- This report provides the Board with an overview of the activities of, and guidance provided by, the Evaluation Advisory Committee (EAC) since the Committee Chair last reported to the Board in June 2024.
- At the in-person EAC meeting held on 24-26 September 2024, and during the virtual meeting on 13 November 2024, the EAC offered guidance on: i) progress on the commissioned/planned Gavi 5.1 centralised evaluations; ii) the proposed evaluations of the African Vaccine Manufacturing Accelerator (AVMA) and the Big Catch-Up; iii) centralised evaluation work planning for Gavi 6.0; iv) the Evaluation Function Review; and v) EAC engagement in Gavi 5.1 evaluations.

Section B: Current evaluation portfolio

- The EAC discussed progress and findings from **Phase 2 of the Zero-Dose Evaluation**. Key findings of / insights from this work included:
 - There is strong alignment on the Zero-Dose Agenda and its objectives exists among core and expanded partners at the national level, but less so at the subnational level within governments, reflecting a gap in localised operational coherence;
 - In terms of partner coordination and joint planning, at the national level, coordination structures, such as inter-agency committees and government-led taskforces, facilitate regular partner engagement, however, government capacity constraints and limited in-country Secretariat presence hinder their functionality. Additionally, while monitoring and accountability systems exist, they are unable to track partner performance effectively and provide results-oriented data on zero-dose, resulting in limited external transparency over core partners' activities and funds and restricted information-sharing between Alliance partners; and
 - Full Portfolio Planning and the Partners' Engagement Framework have enabled alignment and supported Civil Society Organisation participation in zero-dose delivery but are criticised for being overly complex, slow, and disproportionately influenced by core partners.
- The EAC noted that the streamlined approach taken for this work appeared to be characterised by agility to be responsive to emerging questions, and was felt by Secretariat colleagues to have reduced evaluation burden. The EAC recommended to consider this approach again for future evaluations, when relevant.

- With respect to Phase 3 of **the Zero-Dose Evaluation**, the EAC was asked to provide guidance on their view of the value-add of a 3rd Phase of work.
 - The EAC noted that the proposed approach of undertaking a Contribution Analysis in 2025, focusing on outcomes in the Zero-Dose Theory of Change (ToC), would have limited utility due to the current pace of implementation and data availability constraints;
 - Further deep-dive analyses, similar to the approach taken in Phase 2, should be considered if the value add is clear; and
 - Recognising the continued importance of the Zero-Dose agenda in the Gavi 6.0 mission, and the relatively low implementation of Gavi 6.0 programming to date, consideration should be given to planning further Zero-Dose evaluation in Gavi 6.0.
- In relation to **Phase 2 of the COVAX Evaluation**, the EAC did not provide formal guidance at the September EAC meeting. Of note, however:
 - While a final report is due in Q1 2025, emerging insights were used to inform and facilitate the deep dive session at the October 2024 APPT session on partnerships; and
 - The EAC were pleased to note that early lessons were emerging from the joint evaluation process with Alliance partners.
- As an example of the use of evaluation evidence, synthesised insights from across recent evaluations were used to inform the Alliance Partnership and Performance Team (APPT) deep dive sessions in October 2024. At its meeting in October 2024, Programme and Policy Committee (PPC) members praised this effort and requested more synthesis of evaluative evidence to support PPC discussions.
- The Technical Briefing to the PPC and Board in April 2024 on the first year of the Zero-Dose Evaluation and on the Mid-Term Evaluation (MTE) of Gavi's 2021-2025 Strategy was also a successful opportunity to engage with the PPC/Board as the key audience of Gavi's centralised evaluations.
- The following recent evaluations and reports have been published on the Gavi website: i) annual report from the first year of the Zero-Dose Evaluation; and ii) the decentralised evaluation on the use of Mapping for Health (M4H) data. Soon to be available online are: the final report and learning briefs from the second year of the Zero-Dose Evaluation, as well as the final reports of the Country Assessments of the Targeted Country Assistance (TCA) provided through Gavi's Partners' Engagement Framework (PEF) in the Democratic Republic of the Congo (DRC), Ethiopia and Nigeria.

- On further evaluations for Gavi 5.1:
 - The EAC approved the addition to the Gavi 5.1 Centralised Evaluation Workplan of: i) the proposed evaluability assessment of the African Vaccine Manufacturing Accelerator (AVMA); and ii) the proposed evaluation of the Big Catch-Up, subject to further consultations with stakeholders on scoping, data quality and evaluability; and
 - The EAC agreed that the planned evaluation on Sustainability and Transition planned for Gavi 5.0 will have greater impact if shifted to Gavi 6.0, given the importance of, and uncertainty inherent in, the ELTRACO model and broader HSIS Policy in Gavi 6.0. The EAC requested occasional updates from the Centralised Evaluation Team (CET) in relation to this area to help it give useful evaluation guidance in coming cycles.
- The EAC Chair report is attached in the form of a presentation as Annex A and the EAC meeting guidance and decisions are attached as Annex B and C.

Section C: Overarching issues

Development of the Gavi 6.0 Evaluation Workplan

- Regarding the ongoing process to develop the Gavi 6.0 Centralised Evaluation Workplan, the following three overarching topics were discussed in-depth at the EAC meeting in September 2024: i) defining Gavi's vision for country engagement in evaluations at Gavi; and ii) strengthening the categorisation of evaluation types for Gavi, and iii) lessons learned in data collection, evaluation approaches, methodologies and methods for Gavi evaluations. Regarding country engagement in evaluations, the EAC provided guidance that the Gavi Secretariat, with EAC oversight, should clearly articulate and implement a vision for enhanced country and Alliance partner engagement, including evaluation ownership, oversight, question setting, participation, interpretation of findings, and use across its evaluation portfolio.
- Potential evaluation topics for Gavi 6.0 identified through recent consultations with key users including the PPC include: a mid-term evaluation; the promise of new vaccines, i.e. malaria with potential for joint evaluation; the new Fragile and Humanitarian Approach; the zero-dose agenda; the Eligibility, Transition, and Co-financing (ELTRACO) model; Health System Strategy; the contribution of Gavi to country immunisation systems; climate emergency; Universal Health Coverage and Primary Health Care; Gavi's approach to resource allocation and partnerships, including with other Global Health Institutions (GHIs) and with focus on shifts/progress on the Lusaka agenda. It will be important to continue this dialogue with PPC going forward.

Evaluation Function Review

- In relation to the Evaluation Function Review which began in May 2024 to ensure the evaluation function is fit for purpose for Gavi 6.0, the final report was received on 12 November 2024. An Oversight Panel with representation from the PPC, Governance Committee and Gavi's senior leadership was engaged throughout the process to safeguard independence and credibility and to enhance the uptake of the findings and recommendations. The draft findings and recommendations were discussed in September and October with the Senior Leadership Team, the Programmatic Leadership Team, Gavi's Chief Executive Officer (CEO), the Governance Committee, the PPC, and the EAC.
- The final EFR report included a range of recommendations to be addressed to strengthen utility of Gavi's evaluation function and to ensure the right structures, safeguards and processes are in place to enable an independent and robust function (see Annex A).
- The Oversight Panel continued to help steward the decision-making process with a meeting on 13 November 2024 and i) expressed support for ongoing strengthening of the engagement of PPC with evaluation and the use of evaluative evidence to ground PPC discussions on key topics, and ii) supported the Secretariat's proposal to postpone Board approval of a revised Evaluation Policy from June 2025 to December 2025. The EAC also met on this date to discuss the recommendations and requested that EAC Focal Points and the Oversight Panel continue to engage to support the process as it moves to development and implementation of action plans.
- Upcoming engagements with the Board and Committees on the review recommendations and proposed actions include: a Technical Briefing for PPC/Board in January 2025 and engagement with the Governance Committee in Q1 2025. Guidance from the PPC/Board on evaluation needs for Gavi 6.0 will be requested at the Technical Briefing.

Annexes

Annex A: EAC Chair report

Annex B: EAC Meeting Guidance, 24-26 September 2024

Annex C: Review of Decisions, 24-26 September 2024

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING
James Hargreaves
4-5 December 2024, Bali, Indonesia



Overarching issues and guidance


- Current evaluation portfolio
- Development of the Gavi 6.0 Centralised Evaluation Workplan
- Evaluation Function Review

Use of evaluation evidence


- Use of evaluation evidence at Alliance Partnership and Performance Team (APPT) meetings
- PPC requesting more synthesis of the available evaluative evidence to support discussions
- Engaging with PPC/Board in a Technical Briefing on the Mid-Term Evaluation and Zero-Dose (ZD) Evaluation in April 2024

Now available on Gavi's website


Soon available on Gavi's website



MTE of 5.0/5.1




ZD Phase 1




M4H in DRC
(decentralised)



Annual Evaluation
Report 2023



ZD Phase 2



PEF TCA
(decentralised)

Development of the Gavi 6.0 Centralised Evaluation Workplan

Early identification of evaluation needs for key users like the PPC and Board is crucial for providing timely and relevant information

Evaluations at Gavi serve both **learning and accountability purposes**, generating robust evidence for various strategic, programmatic, operational, and organisational questions

For the PPC and Board, evaluation topics of interest focus on **Gavi's strategy progress and areas of strategic importance**. Key evaluation topics should address major evidence gaps, critical or emerging strategic areas, slow progress or implementation challenges, and areas where new evidence would benefit the Alliance partnership

***Guidance on evaluation needs for Gavi 6.0 from PPC/Board will be requested at the PPC/Board Technical Briefing on the EFR in Q1 2025.**

Potential **evaluation topics for Gavi 6.0**, informed by recent reviews and consultations, include:

- ✓ Mid-term evaluation
- ✓ The promise of new vaccines (e.g., malaria)
- ✓ Fragile and Humanitarian Approach
- ✓ Zero-dose agenda
- ✓ Eligibility, Transition, and Co-financing (ELTRACO) model
- ✓ Health System Strategy
- ✓ Gavi's contribution to country immunization systems
- ✓ Climate emergency
- ✓ Universal Health Coverage and Primary Health Care
- ✓ Gavi's approach to resource allocation and partnerships (including with other GHIs/with focus on Lusaka Agenda)

Note: The Gavi 6.0 Centralised Evaluation Workplan is to be approved in Q3/Q4 2025

Gavi 5.1 Centralised Evaluation Workplan


Evaluation		Supplier	Budget	Year							
				2021		2022		2023		2024	
Centralised evaluations of high strategic value to the Board to be commissioned in Gavi 5.1											
Evaluation of Gavi’s initial response to COVID-19		EHG	US\$ 594,000		◊	◊					
COVAX Facility and COVAX AMC formative and baseline study		ITAD	US\$ 1,080,000			◊		◊			
Mid Term Evaluation of Gavi’s 2021-2025 Strategy		EHG	US\$ 921,000			◊	◊	◊		◊	
Evaluation of Gavi’s contribution to reaching zero-dose children and missed communities		IPSOS	US\$ 1,558,108			◊	◊	◊		◊	
Evaluation of the operationalisation of Gavi’s strategy through Gavi’s policies, programmatic guidance, and use of funding levers		EHG	US\$ 569,000		◊		◊	◊			
COVAX Facility and COVAX AMC, phase II		RTI	US\$ 1,339,873					◊		◊	◊
Sustainability/post-transition		TBD	TBD								
African Vaccine Manufacturing Accelerator (AVMA) - Evaluability assessment		TBD	TBD							◊ ◊	
Evaluation of the Big Catch-Up		TBD	TBD							◊ ◊	
	Evaluation commissioning period										
	Evaluation implementation and delivery period										
◊	Deliverable that needs to be seen by the Evaluation Advisory Committee										

Evaluation Function Review (EFR) (1/2)

EFR Recommendations	Progress Update
<p>Several key areas have been identified for strengthening the Gavi evaluation function:</p> <ul style="list-style-type: none"> • Theory of Change (ToC)/shared understanding of the vision/purpose/aims of evaluation for Gavi; • Strengthening ownership/accountability for the Evaluation Policy implementation with an Evaluation Strategy, and PPC mandate update for an enhanced engagement in evaluation; • Strengthening oversight of decentralised evaluation processes; • Ensuring the adequacy of human and activity level resources within CET to meet the requirements for the Gavi 6.0 evaluations; • Strengthening utility with an enhanced/holistic work planning process across evaluative activities and mixed portfolio of evaluations with less focus on 'strategic' and more on 'operational'; • Strengthening the independence of Gavi's evaluation function without undermining utility, including enhanced safeguards for behavioural independence and oversight by PPC; • Reviewing/revising the EAC role and mandate and ensuring the most appropriate/efficient mechanism/s for oversight/advice for credibility, utility and independence; • Strengthening how countries are engaged in evaluation, via an unified approach at country level; • Systematic application of quality assurance (QA) processes across Gavi's evaluations. 	<ul style="list-style-type: none"> • Final report was received on 12 November 2024 • A Technical Briefing for the Board and PPC is planned for early Q1 2025 on recommendations from the EFR and to further explore evaluation needs for Gavi 6.0

Evaluation Function Review (2/2)

Recent and upcoming stakeholder engagement in the EFR process



Key points from the GC meeting (October): i) utility of evidence in decision-making; ii) reducing complexity/transaction costs; iii) strengthening PPC link/ownership of evaluations; iv) Board/PPC request for earlier visibility of evaluative evidence; v) EAC role and mandate.

Key points from the PPC meeting (October): i) potential evaluation topics for Gavi 6.0; ii) importance of joint evaluations and systematic view of evaluation topics; iii) recognition of the value of commencing APPT deep dive sessions with evaluation evidence.

Specific guidance on the centralised evaluation portfolio

Progress update – Sustainability/Post-Transition

Evaluation	Guidance	Progress Update
Gavi's contribution to sustainability of coverage post-transition (evaluation of the enhanced ELTRACO model)	<ul style="list-style-type: none"> Noted that utility for this evaluation work on the enhanced Eligibility, Co-financing and Transition (ELTRACO) model is anticipated post 2025 and that the exact form of this model will not be decided until a decision by the Gavi Board in December 2024; the final ELTRACO and health systems and immunisation strengthening (HSIS) policies in June 2025; and subject to Replenishment outcomes; However, given the centrality and the complexity of this policy, requested that the EAC Focal Points be periodically briefed by the Centralised Evaluation Team (CET) outside of the formal EAC meeting cycle on the questions and issues emerging from the learning agendas on ELTRACO/Middle Income Countries. This would ensure they were in a better position to constructively advise on the nature, terms of reference and timing of the evaluation. This will include suggestions on alternatives to a large retrospective evaluation, and approaches to assessing evaluability; and Mindful of the heavy workload in the CET, the Focal Points will take responsibility for updating EAC at appropriate points until Gavi 6.0. 	<ul style="list-style-type: none"> Postponed

Progress update – Zero-Dose Evaluation, Phase 2

Evaluation	Guidance	Progress Update
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities, phase II	<ul style="list-style-type: none"> • To improve clarity, policy briefs could be renamed to reflect their length and include an executive summary. Recommendations should be clustered for different stakeholders and separate zero-dose-specific issues from broader Gavi-related matters; • Recommendations should align closely with findings, using direct quotes or concrete evidence to enhance credibility; • The streamlined approach for phase 2 evaluation has been effective and should be considered for future evaluations, with pre-meets with EAC Focal Points and suppliers mainstreamed for all centralised evaluations 	<ul style="list-style-type: none"> • Learning briefs received, to soon be published on Gavi's website • Findings used to inform October APPT deep-dives, and development of Gavi 6.0 Strategy and Gavi 6.0 Health System Strategy • Summary report to be received in November 2024

Progress update – Zero-Dose Evaluation, Phase 3

Evaluation	Guidance	Progress Update
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities (Phase 3)	<ul style="list-style-type: none"> • A Contribution Analysis (CA) for 2025 focusing on the Zero-Dose Theory of Change outcomes will have limited utility due to the current pace of implementation and data availability constraints; • As scoping work continues through Q4 2024, the EAC suggests evaluating the value of the proposed Phase 3 work, which includes deep dives into topics already analyzed in 2024, and ongoing consultations with Secretariat business owners; • Given the importance of the Zero-Dose agenda in the Gavi 6.0 mission and the low implementation of Gavi 6.0 programming to date, work planning for Gavi 6.0 should consider commissioning a further Zero-Dose multi-phase evaluation. 	<ul style="list-style-type: none"> • Ongoing reflection re: value-add of the planned Phase 3 in 2025

Progress update – Big Catch-Up and AVMA

Evaluation	Guidance	Progress Update
Evaluation of the African Vaccine Manufacturing Accelerator (AVMA)	<p>Regarding: African Vaccine Manufacturing Accelerator:</p> <ul style="list-style-type: none"> • Ensure triennial reviews and end-line evaluation are linked and complementary • Focus on learning through triennial reviews, with robust documentation of course corrections. • The evaluability assessment should define questions and methods early for effective data collection and support an independent impact analysis at endline. 	<p>AVMA: Subject to further refinement and EAC steers, a final independent evaluation is not expected to occur before 2035.</p> <p>An evaluability assessment is to be considered in 2025.</p>
Evaluation of the Big Catch-up	<p>Regarding: Big Catch-Up:</p> <ul style="list-style-type: none"> • to incorporate questions related to coherence, particularly in terms of alignment with the Zero-Dose Evaluation. <p>For both evaluations:</p> <ul style="list-style-type: none"> • consideration should be given to an appropriate approach to country engagement through the phases of these evaluation processes, by CET, EAC Focal Points, and Alliance Partners, particularly in defining questions, to enhance their relevance and utility. This collaborative effort may lead to more contextually appropriate and actionable insights. 	<p>BCU: Evaluation commissioned for September 2025 with final results in mid 2026.</p>

Progress update – Joint COVAX Evaluation (Phase 2)

Evaluation	Feedback (no formal guidance)	Progress Update
<p>Joint COVAX Evaluation (COVAX Facility and COVAX AMC and Joint Delivery Efforts)</p> <p><i>Joint evaluation with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, UNICEF and WHO</i></p>	<ul style="list-style-type: none"> Expressed cautious optimism that the initial investment will yield significant returns, along with valuable insights from a joint evaluation with Alliance partners. 	<ul style="list-style-type: none"> Emerging insights used to inform October Alliance Partnership and Performance Team (APPT), specific to partnership collaboration and coordination Draft final report to be received in December 2024 Final report due end Q1 2025

Thank you

EAC GUIDANCE

EVALUATION ADVISORY COMMITTEE MEETING
24-26 September 2024, Geneva, Switzerland

Item 3 – Gavi 5.1 Evaluation Workplan Update – Part 1

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- EAC noted that utility for this evaluation work on the enhanced Eligibility, Co-financing and Transition (ELTRACO) model is anticipated post 2025 and that the exact form of this model will not be decided until a decision by the Gavi Board in December 2024; the final ELTRACO and health systems and immunisation strengthening (HSIS) policies in June 2025; and subject to Replenishment outcomes;
- However, given the centrality and the complexity of this policy, requested that the EAC Focal Points be periodically briefed by the Centralised Evaluation Team (CET) outside of the formal EAC meeting cycle on the questions and issues emerging from the learning agendas on ELTRACO/Middle Income Countries. This would ensure they were in a better position to constructively advise on the nature, terms of reference and timing of the evaluation. This will include suggestions on alternatives to a large retrospective evaluation, and approaches to assessing evaluability; and
- Mindful of the heavy workload in the CET, the Focal Points will take responsibility for updating EAC at appropriate points until Gavi 6.0.

Item 4 – Update on the Zero-Dose Evaluation – Phase 2 (1/2)

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Overall, the evaluation has demonstrated quality. However, some policy briefs have limited information regarding accountability or unintended consequences, despite these elements being referenced within the text.
- To improve clarity and utility, the policy briefs could benefit from being renamed to reflect their length, and an executive summary could be included to highlight key issues upfront. Additionally, recommendations could be clustered to better serve the audience by distinguishing between: (1) Gavi Alliance, Secretariat, and country-level stakeholders; and (2) separating zero-dose-specific issues from broader Gavi-related matters.
- While the perspectives of the countries have been well captured, it is essential that the recommendations align closely with the findings to ensure coherence and logical flow. Using direct quotes or concrete evidence from the findings would further enhance the credibility of the recommendations.

Item 4 – Update on the Zero-Dose Evaluation – Phase 2 (2/2)

- The streamlined approach for the phase 2 evaluation has been effective due to its agility, shorter timeframe, and reduced burden on secretariat colleagues. This approach should be considered as a model for future evaluation processes, provided the context is similarly focused. Pre-meets with EAC Focal Points and suppliers should be mainstreamed for all centralised evaluations.

Item 5 – Update on the Zero-Dose Evaluation – Phase 3

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Considering the current pace of implementation, data availability constraints, and the nature of relevant evaluation questions, a Contribution Analysis (CA) for 2025 that focuses on outcomes depicted in the Zero-Dose Theory of Change will have limited utility;
- As further scoping work occurs through Q4 2024, the EAC suggested continued thinking about the value of the proposed work in Phase 3 noting that it proposes deep dives into some of the topics already analysed in 2024, and subject to ongoing consultations including Secretariat business owners; and
- Recognising the continued importance of the Zero-Dose agenda in the Gavi 6.0 mission, and the relatively low implementation of Gavi 6.0 programming to date, consideration should be given in work planning for Gavi 6.0 to commissioning a further Zero-Dose multi-phase evaluation.

Item 7 – Gavi Evaluation Workplan Update – Part 2

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- In relation to the African Vaccine Manufacturing Accelerator:
 - To ensure triennial reviews and the end-line evaluation are appropriately linked and complementary;
 - That a focus on learning through the triennial reviews is appropriate, the EAC notes the importance of robust documentation of course correction throughout this phase; and
 - Additionally, the evaluability assessment should support early definition of the questions and methods for the end-line evaluation to ensure that data is effectively collected and including early stage scoping of the potential value of, and actions needed to support, an independent impact or contribution analysis at endline, given the importance and size of the AVMA investment.
- With respect to the Big Catch-Up, to incorporate questions related to coherence, particularly in terms of alignment with the Zero-Dose Evaluation.
- For both evaluations, consideration should be given to an appropriate approach to country engagement through the phases of these evaluation processes, by CET, EAC Focal Points, and Alliance Partners, particularly in defining questions, to enhance their relevance and utility. This collaborative effort may lead to more contextually appropriate and actionable insights.

Item 8 – Evaluation Policy Operationalisation 1: Evaluation Function Review (1/2)

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance, aligned with the current status of the EFR and for agreement on next steps:

The Evaluation Function Review is still in process and is now behind schedule due to quality issues with the draft report(s), hence the points below are preliminary guidance aimed at supporting the completion of the review, in advance of the final report being received from the suppliers.

At this stage, several key areas have been identified for strengthening the Gavi evaluation function:

- The need for a shared vision for the role and purposes of evaluation relative to other functions;
- Ownership of evaluations;
- Enhancing the usefulness of evaluation at Gavi;
- Stakeholder engagement in evaluations, particularly country partners;
- In the context of Gavi 6.0 it is timely to review the role of the EAC and alignment between the TOR and practice; and
- Further strengthening engagement with the PPC to enhance the evaluation utility.

Item 8 – Evaluation Policy Operationalisation 1: Evaluation Function Review (2/2)

- The EAC Focal Points propose to support a light touch After Action Review to reflect and distil key learning points from the review process to inform future practice for reviews of this type.

Item 9 – Evaluation Policy Operationalisation 2: Gavi 6.0 Work Planning

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- Aligned with the CEO's 180-day plan and Gavi 6.0 direction, the Lusaka Agenda and Gavi Alliance's principles, the Gavi Secretariat should, with EAC oversight, clearly articulate and implement a vision for an enhanced country and Alliance partner engagement (including at least evaluation ownership, oversight, question setting, participation, interpretation of findings, and use) across its evaluation portfolio.

Additional EAC guidance

The Gavi Alliance Evaluation Advisory Committee provided the following formal guidance:

- For future evaluations, data availability limitations should be assessed during the inception phase to ensure that the proposed approaches are feasible;
- The Secretariat could compile a list of relevant data produced by the organisation and ensure that this data is accessible for evaluations as needed;
- The compiled list of data sources could also be useful when putting together Requests for Proposal;
- Efforts should be directed toward developing tools and mechanisms to track Gavi financial resources at the country level given its usefulness for evaluation purposes; and
- Develop a skills matrix for EAC members.

Thank you

REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE MEETING
24-26 September 2024, Geneva, Switzerland

Decision 1: Gavi 5.1 Evaluation Workplan Update – Part 2

The Gavi Alliance Evaluation Advisory Committee:

- **Approved** the revised multi-year (2021-2025) centralised evaluation workplan attached as Annex A to Doc 07.

Thank you